What the business is
A tech-enabled, clinically validated lifestyle-modification platform for cancer patients, survivors and high-risk individuals.
Starting capital
$16 million seed (INR 136.4 Cr) led by Owl Ventures and Blume Ventures.
How it started
Karan Bajaj — who founded WhiteHat Jr in 2018, sold it to BYJU'S for $300 million in 2020, led BYJU'S international division and departed in August 2021 — started Complement1 in 2024 with Trupti Mukker, calling lifestyle change 'one of the most powerful yet underused tools in cancer care'.
What happened
The startup stayed in stealth through its first year, then emerged in May 2025 with the seed round and its first programme: a clinically validated platform working alongside conventional oncology care, claiming to improve outcomes and reduce costs by up to 30% for employers, providers and insurers (company statement).
What has to be true
Oncologists agree patients need lifestyle support, but clinics lack the staff to deliver it daily.
Human coaches plus a platform attack the engagement problem most digital health tools fail at.
The 30%-cost-reduction pitch speaks to employers and insurers, not just patients.
Bajaj's second act rides India's wave of serial founders rebuilding after exits.
What can be applied
A repeat founder's edge is pattern-matching an underserved behaviour problem: daily habits sit outside oncology's remit, so a coaching platform can claim the gap.
Aftermath
As of the May 2025 announcement, Complement1 was launching its first programme out of stealth; no patient, outcome or revenue figures were disclosed.
FOLLOW THE EVIDENCE